Therapies, Treatments, and Procedures

Page 2 of 512345

November 16, 2015

Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

(Updated 12/5/2017) On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian
read more »

November 16, 2015

Lucentis effective for proliferative diabetic retinopathy

Posted in: Latest News, Therapies, Treatments, and Procedures

NIH-funded clinical trial marks first major advance in therapy in 40 years A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser
read more »

April 3, 2015

Phase 2 Stem Cell Trial To Be Initiated

Posted in: Latest News, Therapies, Treatments, and Procedures

Ocata Therapeutics, Inc. (now owned by Acucela) announced on March 31, 2015 that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt’s Macular Degeneration (SMD). A total of 38 patients have been safely dosed. The 200,000 cell cohort, the highest level planned, was successfully completed, paving
read more »

February 7, 2015

FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema

Posted in: Latest News, Therapies, Treatments, and Procedures

The U.S. Food and Drug Administration announced today that they have expanded the approved use for Lucentis 0.3 mg (Genentech) to treat diabetic retinopathy in patients with diabetic macular edema. The FDA previously had approved Lucentis to treat DME and macular edema secondary to retinal vein occlusions, both of which cause fluid to leak into
read more »

September 30, 2014

FDA Approves Two Extended-Release Drug Therapies For DME

Posted in: Latest News, Therapies, Treatments, and Procedures

By Dan Roberts Implants devised by two different companies for treatment of diabetic macular edema (DME) have been approved by the FDA for use in the United States. The companies are Allergan and Alimera, and the new drugs are Ozurdex and Iluvien respectively. Both drugs are corticosteroids that have demonstrated effectiveness in the treatment of
read more »

April 29, 2014

Experimental Therapies for CSR

Posted in: Research and Developments, Therapies, Treatments, and Procedures

by Dan Roberts April 2014 Updated September 8, 2015 Research has shown that corticosteroids produced by the body (endogenous) and administered externally (exogenous) can raise adrenaline levels, which can harm the central retina. Some people have high levels of endogenous steroids that can lead to a condition called central serous retinopathy (CSR), aka central serous
read more »

January 29, 2014

U-M Kellogg Eye Center performs first two retinal prosthesis implants in U.S. since FDA approval

Posted in: Latest News, Therapies, Treatments, and Procedures

Kellogg retina surgeons implant Argus II Retinal Prosthesis, or ‘bionic eye,’ for two patients with end-stage retinitis pigmentosa ANN ARBOR, Mich. — Retina surgeons at the University of Michigan Kellogg Eye Center have performed the first – and second – surgeries in the United States to implant an artificial retina, or “bionic eye,” since the U.S. Food and
read more »

December 11, 2013

Time Between Lucentis and Eylea Treatments Found To Be Similar

Posted in: Latest News, Therapies, Treatments, and Procedures

The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days
read more »

October 3, 2013

New Drug Effective in Treating Vitreous Traction

Posted in: Latest News, Therapies, Treatments, and Procedures

Early treatment with a new drug called JETREA® (formerly called ocriplasmin) has shown effectiveness in lessening the risk of macular pucker, macular hole, and vitreomacular traction (VMT). These conditions are caused by the tugging on the macula by the vitreous gel, which is attached to the retina at several points. As the vitreous shrinks with
read more »

September 24, 2013

Non-Mydriatic Retinal Cameras Offer Safer Examination

Posted in: Latest News, Therapies, Treatments, and Procedures

by Liz Trauernicht, Director MD Foundation A significant amount of evidence finds that very bright light, especially blue light, can damage the macula. Traditional slit lamp devices used during eye exams produce high light levels, which may be problematic for people with macular degeneration. Before these devices can be used effectively, the pupil of the
read more »

Page 2 of 512345

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann